wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 18. no 2. June 2013  

 Original articles
Clinical effectiveness of omalizumab during a 5-year follow-up
Roman Skiepko, Ziemowit Ziętkowski, Urszula Skiepko, Wojciech Budny, Anna Bodzenta-Łukaszyk

Introduction. So far, no clear criteria are available which could be used to assess effectiveness of asthma treatment. The lack of such criteria is related with divergences in the assessment of: pulmonary parameters, asthma control criteria, quality of life reported by patients, frequency of asthma exacerbations and the necessity of hospitalization, as well as biochemical and histological indicators of the inflammatory process. It is advisable to find and estimate indices which can help in long term evaluation of omalizumab treatment.
Aim. The aim of the study was the evaluation of clinical effectiveness of omalizumab in patients with uncontrolled allergic asthma with regard to selected indices in a 5-year follow-up.
Materials and methods. The study was performed in a group of 13 patients with chronic severe asthma according to GINA 2006 criteria, treated with omalizumab in 2007-2011. The assay of the effectiveness of the treatment was based on: ACT, FEV1, doses of ICS and OCS, use of rescue medication and frequency of exacerbations.
Results. Improvement of the selected indices was observed after 16 weeks of the treatment.
5-year follow-up showed further tendency for improvement of the studied parameters, including lower frequency of exacerbations, less frequent use of rescue medication procedure and reduced long-term intake of oral glycocorticosteroids.
Conclusions. Our results show that omalizumab is effective for improving clinical indices of asthma severity and spirometry tests in patients with severe chronic allergic asthma in whom asthma control could not be achieved by other medication.

keywords: astma, omalizumab, skuteczność kliniczna, asthma, omalizumab, clinical efficacy

pages: from 104 to 109

estimated time of download (327 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.